Validation of albumin platelet product as a non-invasive fibrosis staging tool in patients with chronic HCV-related liver disease
Abstract Background and aim: The Albumin Platelet Product (APP) has emerged as a promising non-invasive biomarker for fibrosis staging in chronic liver disease (CLD). This cross-sectional study aims to evaluate the effectiveness of APP compared to established non-invasive markers of fibrosis in an E...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-06-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-07456-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849420638703321088 |
|---|---|
| author | Maha Elsabaawy Mohamed Eissa Ahmed Shaban Madiha Naguib |
| author_facet | Maha Elsabaawy Mohamed Eissa Ahmed Shaban Madiha Naguib |
| author_sort | Maha Elsabaawy |
| collection | DOAJ |
| description | Abstract Background and aim: The Albumin Platelet Product (APP) has emerged as a promising non-invasive biomarker for fibrosis staging in chronic liver disease (CLD). This cross-sectional study aims to evaluate the effectiveness of APP compared to established non-invasive markers of fibrosis in an Egyptian cohort with HCV-related CLD. Methods: 580 participants were assessed across different fibrosis stages (F0-F4) to analyze the relationship between APP and liver fibrosis. APP was compared with FIB-4 and APRI scores for diagnostic performance. Results: The study included 580 patients with HCV-related CLD (mean age: 37.6 ± 9.66 years; 74.3% males). APP proved superiority in identifying liver cirrhosis (F4) at Cut-off values ≤ 0.59 with 81% sensitivity, 63.6% specificity (p < 0.001). APP showed a significant correlation with fibrosis stages, with an AUC of 0.920 (95% CI: 0.888–0.953) for distinguishing F4 from F0-F3 surpassing both FIB4 and APRI scores. However, FIB-4 proved superiority in distinguishing advanced fibrosis (F ≥ 3) with AUC of 0.899 (95% CI: 0.871–0.927) compared to APP with AUC of 0.87 (95% CI: 0.84–0.90), respectively. Multivariate analysis confirmed APP as an independent predictor of fibrosis (OR: 0.997, 95% CI: 0.995–0.998; p < 0.001). Conclusion: APP showed the highest performance in predicting cirrhosis, suggesting its potential as a simple, non-invasive marker for identifying patients with advanced liver disease. Its integration into clinical practice may enhance early detection and risk stratification in chronic HCV-related fibrosis. However, further multicenter, longitudinal studies are required to validate its efficacy across diverse populations and other liver disease etiologies. |
| format | Article |
| id | doaj-art-3199f85b98af4192b9fb533d397dc9e1 |
| institution | Kabale University |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-3199f85b98af4192b9fb533d397dc9e12025-08-20T03:31:41ZengNature PortfolioScientific Reports2045-23222025-06-011511910.1038/s41598-025-07456-xValidation of albumin platelet product as a non-invasive fibrosis staging tool in patients with chronic HCV-related liver diseaseMaha Elsabaawy0Mohamed Eissa1Ahmed Shaban2Madiha Naguib3Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia UniversityDepartment of Hepatology and Gastroenterology, National Liver Institute, Menoufia UniversityDepartment of Hepatology and Gastroenterology, National Liver Institute, Menoufia UniversityDepartment of Hepatology and Gastroenterology, National Liver Institute, Menoufia UniversityAbstract Background and aim: The Albumin Platelet Product (APP) has emerged as a promising non-invasive biomarker for fibrosis staging in chronic liver disease (CLD). This cross-sectional study aims to evaluate the effectiveness of APP compared to established non-invasive markers of fibrosis in an Egyptian cohort with HCV-related CLD. Methods: 580 participants were assessed across different fibrosis stages (F0-F4) to analyze the relationship between APP and liver fibrosis. APP was compared with FIB-4 and APRI scores for diagnostic performance. Results: The study included 580 patients with HCV-related CLD (mean age: 37.6 ± 9.66 years; 74.3% males). APP proved superiority in identifying liver cirrhosis (F4) at Cut-off values ≤ 0.59 with 81% sensitivity, 63.6% specificity (p < 0.001). APP showed a significant correlation with fibrosis stages, with an AUC of 0.920 (95% CI: 0.888–0.953) for distinguishing F4 from F0-F3 surpassing both FIB4 and APRI scores. However, FIB-4 proved superiority in distinguishing advanced fibrosis (F ≥ 3) with AUC of 0.899 (95% CI: 0.871–0.927) compared to APP with AUC of 0.87 (95% CI: 0.84–0.90), respectively. Multivariate analysis confirmed APP as an independent predictor of fibrosis (OR: 0.997, 95% CI: 0.995–0.998; p < 0.001). Conclusion: APP showed the highest performance in predicting cirrhosis, suggesting its potential as a simple, non-invasive marker for identifying patients with advanced liver disease. Its integration into clinical practice may enhance early detection and risk stratification in chronic HCV-related fibrosis. However, further multicenter, longitudinal studies are required to validate its efficacy across diverse populations and other liver disease etiologies.https://doi.org/10.1038/s41598-025-07456-xAlbumin platelet product (APP)FibrosisHepatitis C virus (HCV)Non-invasive fibrosis markers |
| spellingShingle | Maha Elsabaawy Mohamed Eissa Ahmed Shaban Madiha Naguib Validation of albumin platelet product as a non-invasive fibrosis staging tool in patients with chronic HCV-related liver disease Scientific Reports Albumin platelet product (APP) Fibrosis Hepatitis C virus (HCV) Non-invasive fibrosis markers |
| title | Validation of albumin platelet product as a non-invasive fibrosis staging tool in patients with chronic HCV-related liver disease |
| title_full | Validation of albumin platelet product as a non-invasive fibrosis staging tool in patients with chronic HCV-related liver disease |
| title_fullStr | Validation of albumin platelet product as a non-invasive fibrosis staging tool in patients with chronic HCV-related liver disease |
| title_full_unstemmed | Validation of albumin platelet product as a non-invasive fibrosis staging tool in patients with chronic HCV-related liver disease |
| title_short | Validation of albumin platelet product as a non-invasive fibrosis staging tool in patients with chronic HCV-related liver disease |
| title_sort | validation of albumin platelet product as a non invasive fibrosis staging tool in patients with chronic hcv related liver disease |
| topic | Albumin platelet product (APP) Fibrosis Hepatitis C virus (HCV) Non-invasive fibrosis markers |
| url | https://doi.org/10.1038/s41598-025-07456-x |
| work_keys_str_mv | AT mahaelsabaawy validationofalbuminplateletproductasanoninvasivefibrosisstagingtoolinpatientswithchronichcvrelatedliverdisease AT mohamedeissa validationofalbuminplateletproductasanoninvasivefibrosisstagingtoolinpatientswithchronichcvrelatedliverdisease AT ahmedshaban validationofalbuminplateletproductasanoninvasivefibrosisstagingtoolinpatientswithchronichcvrelatedliverdisease AT madihanaguib validationofalbuminplateletproductasanoninvasivefibrosisstagingtoolinpatientswithchronichcvrelatedliverdisease |